OSE Immunotherapeutics SA (ORPOF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 10:31AM EDT
| Previous Close | 11.60 |
| Open | 11.60 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 11.60 - 11.60 |
| 52 Week Range | 11.60 - 11.60 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | 144.876M |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.97 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
NANTES, France, May 18, 2022--OSE Announces Dosing of the First Participant in a Phase 1 of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
- Business Wire
OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston
NANTES, France, May 11, 2022--OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston.
- Business Wire
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology
NANTES, France, May 03, 2022--Boehringer Ingelheim and OSE Immuno Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063.
© 2022 Yahoo. All rights reserved.
